Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SeluDex: Selumetinib + Dexamethasone in R/R RAS-mutated ALL
NCT03705507Phase 2Terminated
- Sponsor
- University of Birmingham
- Start
- May 2018
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of selumetinib in acute lymphoblastic leukemia (ALL), sponsored by University of Birmingham. Started May 2018; status: terminated.
02
Drugs
selumetinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT03705507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03705507.